期刊文献+

疾病分期在47例特发性肺纤维化中的临床价值 被引量:4

Value of clinical staging for idiopathic pulmonary fibrosis
原文传递
导出
摘要 目的了解GAP评分和分期系统对特发性肺纤维化(IPF)预后的临床价值。方法回顾性分析47例北京市第六医院住院明确诊断的IPF患者,27例完善支气管肺泡灌洗,对全部病例进行GAP指数评估及分期,分析各期患者生存情况及氧分压(POz)变化,了解各期患者的临床特征,并进一步评价预后。结果Ⅲ期IPF患者的3年及5年生存率分别为40.0%及30.0%,中位生存期为27.1个月,P02为(48.7±8.1)mmHg,明显低于Ⅰ、Ⅱ期(P〈0.01);C反应蛋白为(27.4±17.5)mg/L,高于Ⅰ、Ⅱ期(P〈O.05);支气管肺泡灌洗液(BALF)中中性粒细胞比例和嗜酸粒细胞比例分别为(9.9±3.O)%及(6.3±2.3)%,高于Ⅰ、Ⅱ期(P〈O.05或P〈O.01)。Ⅱ、Ⅲ期IPF患者肿瘤标记物异常及合并肺动脉高压的比例增多(P〈0.05或P〈O.01),Ⅲ期IPF患者急性发作发生率高于Ⅰ、Ⅱ期(P〈0.05)。血沉、职业暴露、吸烟及合并慢性阻塞性肺疾病、肺癌、反流性食管炎在各期分布差异无统计学意义(P〉O.05)。结论Ⅲ期IPF患者生存情况差,POz低下,C反应蛋白、BALF中中性粒细胞比例和嗜酸粒细胞比例升高,肿瘤标记物异常比例、并发肺动脉高压及急性发作发生率增多,临床预后不良。 Objective To investigate the clinical value of GAP risk assessment system and staging for the prognosis evaluation of idiopathic pulmonary fibrosis. Methods The data of 47 patients with idiopathic pulmonary fibrosis were analysed retrospectively, in which bronchoalveolar lavage fluid were detected in 27 patients, risk evaluation on the basis of GAP risk assessment system and staging were conducted for all patients. Results Survival rate for three years and five years of the patients staged Ⅲ was 40.0% and 30.0% respectively, 27.1 months for mean survival time, (48.7 ± 8.1) mm Hg for arterial partial pressure of oxygen, which were inferior than that of staged Ⅰ and Ⅱ ( P d0.01). There were higher level of C-reactive protein, neutrophil and eosinophil percent in bronchoalveolar lavage fluid, and acute episode frequency for the patients staged Ⅲ. Tumor marker abnormal ratio and complicating pulmonary artery hypertension were higher for the patients staged Ⅱ and Ⅲ. Conclusions Patients with idiopathic pulmonary fibrosis stagedⅢ have bad survival status and clinical prognosis.
出处 《国际呼吸杂志》 2013年第10期752-755,共4页 International Journal of Respiration
关键词 特发性肺纤维化 GAP指数评估 分期 预后 Idiopathic pulmonary fibrosis GAP risk assessment system Staging Prognosis
  • 相关文献

参考文献12

二级参考文献136

  • 1中华医学会呼吸病学分会.特发性肺问质纤维化诊断和治疗指南(草案).中华结核和呼吸杂志,2002,25(7):388-388.
  • 2King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gammalb for idiopathic pulmonary fibrosis. Chest, 2005,127 : 171-177.
  • 3Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med, 2003, 168: 543-548.
  • 4Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2009, 179:402-407.
  • 5Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopuhnonary exercise testing. Circulation, 2002, 106 : 319- 324.
  • 6Iwasawa T, Asakura A, Sakai F, et al. Assessment of prognosis of patients with idiopathic pulmonary fibrosis by computer-aided analysis of CT images. J Thorac Imaging, 2009, 24:216-222.
  • 7Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP : survival implications. Thorax, 2003, 58 : 143-148.
  • 8Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med, 2008, 177:433-439.
  • 9Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology, 2008, 246:935-940.
  • 10Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med, 2004, 351 : 1655-1665.

共引文献340

同被引文献24

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部